Methotrexate in the treatment of atopic dermatitis.

IF 1.4 4区 医学 Q3 ALLERGY
Postepy Dermatologii I Alergologii Pub Date : 2025-04-15 eCollection Date: 2025-06-01 DOI:10.5114/ada.2025.149551
Roman J Nowicki, Elżbieta Grubska-Suchanek, Aleksandra Wilkowska, Dmitrij F Khvorik, Magdalena Trzeciak
{"title":"Methotrexate in the treatment of atopic dermatitis.","authors":"Roman J Nowicki, Elżbieta Grubska-Suchanek, Aleksandra Wilkowska, Dmitrij F Khvorik, Magdalena Trzeciak","doi":"10.5114/ada.2025.149551","DOIUrl":null,"url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a common inflammatory skin disease. Most cases start in children although some have been reported in adults. Moderate to severe cases of AD not responding to topical treatments may need systemic therapy. Methotrexate may be considered in patients with severe AD who did not achieve the expected improvement after cyclosporine, or who had adverse effects and no possibility of biological treatment with monoclonal antibodies or Janus kinase inhibitors.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"42 3","pages":"243-247"},"PeriodicalIF":1.4000,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12262029/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Postepy Dermatologii I Alergologii","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5114/ada.2025.149551","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Atopic dermatitis (AD) is a common inflammatory skin disease. Most cases start in children although some have been reported in adults. Moderate to severe cases of AD not responding to topical treatments may need systemic therapy. Methotrexate may be considered in patients with severe AD who did not achieve the expected improvement after cyclosporine, or who had adverse effects and no possibility of biological treatment with monoclonal antibodies or Janus kinase inhibitors.

甲氨蝶呤治疗特应性皮炎。
特应性皮炎(AD)是一种常见的炎症性皮肤病。大多数病例始于儿童,尽管也有一些报告发生在成人身上。局部治疗无效的中度至重度AD病例可能需要全身治疗。重度AD患者在环孢素治疗后未达到预期改善,或出现不良反应且无法用单克隆抗体或Janus激酶抑制剂进行生物治疗时,可考虑使用甲氨蝶呤。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.60
自引率
7.10%
发文量
107
审稿时长
6-12 weeks
期刊介绍: Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii is a bimonthly aimed at allergologists and dermatologists.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信